Safety and biodistribution of an equine infectious anemia virus-based gene therapy, retinostat®, for age-related macular degeneration

Human Gene Therapy

Volumn 23, Issue 9, 2012, Pages 980-991

  Binley, Katie ^a   Widdowson, Peter S ^a   Kelleher, Michelle ^a   De Belin, Jackie ^a   Loader, Julie ^a   Ferrige, Georgina ^a   Carlucci, Marie ^a   Esapa, Margaret ^a   Chipchase, Daniel ^a   Angell Manning, Diana ^a   Ellis, Scott ^a   Mitrophanous, Kyriacos ^a   Miskin, James ^a   Bantseev, Vlad ^b,c   Michael Nork, T ^d   Miller, Paul ^d   Naylor, Stuart ^a  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b 206 Carnegie Center   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ENDOSTATIN; RETINOSTAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ARTICLE; CELL INFILTRATION; CHOROID; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SAFETY; EQUINE INFECTIOUS ANEMIA VIRUS; EYE; EYE EXAMINATION; HISTOLOGY; INTRAOCULAR PRESSURE; MACACA; MONONUCLEAR CELL; NONHUMAN; RABBIT; RETINA; RETINA MACULA AGE RELATED DEGENERATION; VIRAL GENE THERAPY; VITREOUS BODY;

ANGIOSTATINS; ANIMALS; ENDOSTATINS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INFECTIOUS ANEMIA VIRUS, EQUINE; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MACULAR DEGENERATION; RABBITS; TIME FACTORS; VITREOUS BODY;

EQUINE INFECTIOUS ANEMIA VIRUS; MACACA; MACACA MULATTA; ORYCTOLAGUS CUNICULUS;

EID: 84866306907     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.008     Document Type: Article

References (32)

1. Azzouz, M., Martin-Rendon, E., Barber, R.D., et al. (2002) Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic l-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci. 22, 10302-10312. (Pubitemid 35416868)
2. Bainbridge, J.W., Smith, A.J., Barker, S.S., et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239. (Pubitemid 351724452)
3. Balaggan, K.S., Binley, K., Esapa, M., et al. (2006). Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors J. Gene Med. 8, 275-285.
4. Bienemann, A.S., Martin-Rendon, E., Cosgrave, A.S., et al. (2003). Long-term replacement of a mutated nonfunctional CNS gene: Reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin. Mol. Ther. 7, 588-596. (Pubitemid 36626238)
5. Brown, D.M., Kaiser, P.K., Michels, M., et al. (2006). ANCHOR study group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432-1444. (Pubitemid 44511558)
6. Campochiaro, P.A., Nguyen, Q.D., Shah, S.M., et al. (2006). Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial. Hum. Gene Ther. 17, 167-176. (Pubitemid 43262032)
7. DePolo, N.J., Reed, J.D., Sheridan, P.L., et al. (2000). VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol. Ther. 2, 218-222.
8. Hamirally, S., Fernandes, A., Wong, P., et al. (2009). Effective photoreceptor and RPE transduction using EIAV-based lentiviral vector expressing GFP following ocular delivery in the nonhuman primatemodel. Invest.Ophthalmol.Vis. Sci. 50, 3026.
9. Hauswirth, W.W., Aleman, T.S., Kaushal, S., et al. (2008). Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase 1 trial. Hum. Gene Ther. 19, 979-990.
10. Husain, D., Kim, I., Gauthier, D., et al. (2005). Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularisation in the monkey. Arch. Ophthalmol. 123, 509-516. (Pubitemid 40489924)
11. Jacobson, S.G., Boye, S.L., Aleman, T.S., et al. (2006). Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum. Gene Ther. 17, 845-858. (Pubitemid 44681454)
12. Kaiser, P.K., Symons, R.C., Shah, S.M., et al. (2010). RNAi-based treatment for neovascular age-related macular degeneration by siRNA-027. Am. J. Ophthalmol. 150, 33-39.
13. Lai, C.M., Estcourt, M.J., Himbeck, R.P., et al. (2011). Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther. 1-11.
14. Lamikanra, A., Myers, K.A., Ferris, N., et al. (2005). In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies. Gene Ther. 12, 988-998. (Pubitemid 40903421)
15. Macclachlan, T.K., Lukason, M., Collins, M., et al. (2011). Preclinical safety evaluation of AAV2-sFLT01-a gene therapy for age-related macular degeneration. Am. Soc. Gene Cell Ther. 19, 326-334.
16. Maguire, A.M., Simonelli, F., Pierce, E.A., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248. (Pubitemid 351724453)
17. Miskin, J., Chipchase, D., Rohll, J., et al (2006). A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectors. Gene Ther. 13, 196-205. (Pubitemid 43148642)
18. Mitrophanous, K., Yoon, S., Rohll, J., et al. (1999). Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6, 1808-1818. (Pubitemid 29531276)
19. Nork, T, M., Murphy, C.J., Kim, C.B., et al. (2012). Functional and anatomic consequences of subretinal dosing in the cynomolgus macaque. Arch. Ophthalmol. 130, 65-75.
20. Rasmussen, H.S., Smith, A.C., Durham, R.J., et al. (2003). Safety of intravitreal adenoviral gene therapy containing human pigment epithelium-derived pigment derived factor in monkeys. Preclinica 1, 77-85.
21. Rohll, J.B., Mitrophanous, K.A., Martin-Rendon, E., et al. (2002). Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. Methods Enzymol. 346, 466-500. (Pubitemid 41103154)
22. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. (2006). MARINA study group: Ranibizumab for neovascular age-related macular degeneration . N. Engl. J. Med. 355, 1419-1431. (Pubitemid 44511557)
23. Scappaticci, F.A., Smith, R., Pathak, A., et al. (2001). Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol. Ther. 3, 186-196. (Pubitemid 32509821)
24. Schwab, I.R. (2011). Evolution's Witness: How Eyes Evolved. (Oxford University Press, Oxford) Appendix B, p. 252.
25. Sellon, D.C., Perry, S.T., Coggins, L., et al. (1992). Wild-type equine infectious anaemia virus replicates in vivo predominantly in tissue macrophages, not in peripheral blood monocytes. J. Virol. 66, 5906-5913.
26. Sickenberg, M. (2001). Early detection, diagnosis and management of choroidal neovascularization in age-related macular degeneration: The role of ophthalmologists. Ophthalmologica 215, 247-253. (Pubitemid 32588881)
27. Simonelli, F., Maguire, A.M., Testa, F., et al. (2010). Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 18, 643-650.
28. Stewart, H.J., Leroux-Carlucci, M.A., Sion, C.J.M., et al. (2009). Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. Gene Ther. 16, 805-814.
29. Truran, R., Buckley, R., Radcliffe, P., Miskin, J., and Mitrophanous, K.; for Oxford Biomedica (UK). (2009). Virus purification. Patent WO/2009/153563. December 23, 2009.
30. Wanisch, K., and Yáñ ez-Muñ oz, R.J. (2009). Integration-deficient lentiviral vectors: A slow coming of age. Mol. Ther. 17, 1316-1332.
31. Yokoyama, Y., Dhanabal, M., Griffioen, A.W. et al. (2000). Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth. Cancer Res. 60, 2190-2196. (Pubitemid 30225182)
32. Yu, D.Y., and Cringle, S.J. (2004). Low oxygen consumption in the inner retina of the visual streak of the rabbit. Am. J. Physiol. Heart Circ. Physiol. 286, H419-H423. (Pubitemid 38049508)